Gilead Sciences, Inc.

Gilead Sciences, Inc. is listed in filings as 10% Owner at Xilio Therapeutics, Inc.. This profile follows SEC Form 4 activity through May 27, 2026, including purchase activity. Recent filings connect the profile to Xilio Therapeutics, Inc. (XLO), Arcus Biosciences, Inc. (RCUS), and Assembly Biosciences, Inc. (ASMB). The current snapshot covers public activity from Jun 20, 2024 to May 27, 2026. Reported amounts are shown as $1.8M to $10.0M. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.